Table 3 Incidence rate of functional deterioration by different variables
Pacs-semester | Events | TM 100 pacs-semester | IC 95% | |
|---|---|---|---|---|
Hospital centers | ||||
FJD | 238.4 | 59 | 24.7 | 19.2–31.9 |
HCSC | 150.1 | 36 | 23.9 | 17.3–33.2 |
HiLe | 5.7 | 0 | 0 | – |
HIS | 6.9 | 0 | 0 | – |
HPH | 33.7 | 12 | 35.6 | 20.2–62.7 |
HUG | 9.2 | 0 | 0 | – |
HULP | 18.8 | 4 | 21.3 | 7.9–56.7 |
Gender | ||||
Women | 325.5 | 79 | 24.3 | 19.4–30.2 |
Men | 137.3 | 32 | 23.3 | 16.4–32.9 |
Age in years | ||||
≤ 60 | 156.9 | 34 | 21.6 | 15.5–30.3 |
60–69 | 164.0 | 43 | 26.2 | 19.4–35.3 |
70–79 | 93.4 | 26 | 27.8 | 18.9–40.9 |
≥ 80 | 48.5 | 8 | 16.5 | 8.2–32.9 |
Active-former smokers | ||||
No | 155.8 | 43 | 27.6 | 20.4–37.2 |
Yes | 307.0 | 68 | 22.15 | 17.4–28.09 |
Comorbidity overall | ||||
No | 145.8 | 36 | 24.6 | 17.8–34.2 |
Yes | 302.3 | 72 | 23.9 | 18.9–30.0 |
Comorbidity types | ||||
CV disease | ||||
No | 225.5 | 49 | 21.7 | 16.4–28.7 |
Yes | 222.6 | 59 | 26.5 | 20.5–34.2 |
History of cancer | ||||
No | 417.6 | 106 | 25.4 | 20.9–30.7 |
Yes | 30.4 | 2 | 6.4 | 1.6–26.2 |
Liver disease | ||||
No | 410.6 | 100 | 24.3 | 20.00–29.6 |
Yes | 37.5 | 8 | 21.3 | 10.6–42.6 |
COPD-Bronchiectasis | ||||
Yes | 395.6 | 104 | 26.3 | 21.7–31.8 |
No | 50.4 | 3 | 5.9 | 1.9–18.44 |
Renal failure | ||||
Yes | 446.6 | 108 | 24.18 | 20.0–29.2 |
No | 1.5 | 0 | 0 | – |
Hypothyroidism | ||||
Yes | 397.6 | 94 | 23.7 | 19.3–28.9 |
No | 50.6 | 14 | 27.7 | 6.6–63.3 |
GER | ||||
Yes | 403.5 | 97 | 24.0 | 19.7–29.3 |
No | 40.2 | 10 | 24.8 | 13.4–46.3 |
Radiological ILD pattern | ||||
NSIP | 236.7 | 45 | 19.0 | 14.1–25.4 |
UIP | 153.5 | 50 | 32.2 | 24.6–42.9 |
Others | 72.5 | 16 | 22.0 | 13.5–36.0 |
Emphysema (HRTC)(n = 54) | ||||
No | 273.5 | 67 | 24.5 | 19.3–31.1 |
Yes | 68.1 | 32 | 17.6 | 10.0–31.0 |
Fibrosis (HRTC) (n = 54) | ||||
No | 189.5 | 40 | 21.1 | 15.5–28.8 |
Yes | 134.5 | 37 | 27.5 | 19.9–37.9 |
FVC% | ||||
< 80 | 155.9 | 39 | 25.0 | 18.3–34.2 |
> 80 | 306.9 | 72 | 23.4 | 18.6–29.5 |
DLCO (n = 68) | ||||
< 60 | 138.7 | 38 | 27.3 | 19.8–37.6 |
> 60 | 237.8 | 62 | 26.1 | 20.3–33.4 |
Rheumatoid Factor (n = 65) | ||||
Negative | 310.4 | 82 | 26.4 | 21.3–32.8 |
Positive | 97.9 | 22 | 22.5 | 14.8–34.1 |
ANA antibodies (n = 73) | ||||
Negative | 113.9 | 18 | 15.7 | 9.9–25.07 |
Positive | 336.3 | 90 | 26.7 | 21.7–32.9 |
Ro antibodies (n = 72) | ||||
Negative | 313.12 | 85 | 27.1 | 21.9–33.6 |
Positive | 99.1 | 16 | 16.1 | 9.8–26.3 |
Glucocorticoids during follow-up | ||||
No | 184.6 | 43 | 23.3 | 17.2–31.3 |
Yes | 278.2 | 68 | 24.4 | 19.3–31.0 |
DMARDs during follow-up | ||||
MTX-LEF-AM | ||||
No | 432.7 | 103 | 23.8 | 19.6–28.9 |
Yes | 30.1 | 8 | 26.5 | 13.3–53.0 |
AZA-MMF | ||||
No | 321.2 | 71 | 22.1 | 17.5–27.8 |
Yes | 141.6 | 40 | 28.2 | 20.7–38.5 |
Cyclosporin-Tacrolimus | ||||
No | 432.5 | 106 | 24.2 | 20.3–29.6 |
Yes | 30.3 | 5 | 16.5 | 6.8–39.6 |
Biologic agents (RTX) | ||||
No | 429.0 | 102 | 23.7 | 19.5–28.8 |
Yes | 33.8 | 9 | 26.6 | 13.8–51.1 |
Antifibrotic agents during follow-up | ||||
No | 439.1 | 106 | 23.9 | 19.7–28.9 |
Yes | 23.76 | 6 | 25.2 | 11.3–56.1 |